mycophenolic-acid has been researched along with Non-alcoholic-Fatty-Liver-Disease* in 2 studies
2 other study(ies) available for mycophenolic-acid and Non-alcoholic-Fatty-Liver-Disease
Article | Year |
---|---|
Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed.
Non-alcoholic fatty liver disease (NAFLD) is nowadays the most common liver disease worldwide. Autoimmune hepatitis (AIH) is a relatively rare disease of the liver characterised by female predominance, circulating autoantibodies, polyclonal hypergammaglobulinaemia, interface hepatitis on histology and favourable response to immunosuppression. The possibility of an additional AIH diagnosis in patients with NAFLD (NAFLD/AIH concurrence) or the presence of AIH alone instead of a supposed NAFLD diagnosis represents a challenge for clinicians. We report herein two adult patients (a 33-year-old woman and a 59-year-old man) with a previous NAFLD diagnosis who proved finally to suffer from AIH alone. These two representative cases indicate how difficult and complicated could be sometimes the diagnosis of patients with AIH highlighting the range of disease manifestations and severity while they also underline that although NAFLD is by far the most frequent chronic liver disease this could not be always the case. Topics: Adult; Antibodies, Antinuclear; Biopsy; Diagnosis, Differential; Diagnostic Errors; Elasticity Imaging Techniques; Female; Hepatitis, Autoimmune; Humans; Immunoglobulin G; Immunosuppressive Agents; Liver; Liver Function Tests; Male; Metabolic Syndrome; Middle Aged; Mycophenolic Acid; Non-alcoholic Fatty Liver Disease; Obesity, Morbid; Prednisolone | 2020 |
Prevalence and risk factors of steatosis after liver transplantation and patient outcomes.
Steatosis occurs frequently after liver transplantation (LT). We aimed to determine the prevalence of steatosis in adult LT recipients, to determine the effects of significant (>33%; grades 2-3) steatosis on patient survival, and to identify risk factors for the development of significant steatosis and its effect on fibrosis progression. We retrospectively examined 2360 posttransplant biopsies of 548 LT recipients. Survival was compared between patients with significant steatosis and those with grades 0-1 steatosis. Patients with significant steatosis were compared to controls without steatosis (grade 0) for clinical and laboratory factors and fibrosis progression. Steatosis was found in 309 (56.4%) patients, including 93 (17.0%) patients with significant steatosis. Steatohepatitis (nonalcoholic fatty liver disease activity score ≥ 5) was diagnosed in 57 (10.4%) patients. The prevalence of steatosis increased from 30.3% at 1 year to 47.6% at 10 years after LT (P < 0.001). Survival times did not differ between groups (P = 0.29). On multivariate analysis of pretransplant factors and initial immunosuppression (IS), alcohol-induced cirrhosis (P < 0.001) and high body mass index (BMI; P = 0.002) were associated with the development of significant steatosis, whereas increased levels of alkaline phosphatase (P = 0.01) and mycophenolate mofetil given initially (P = 0.009) appeared to protect against significant steatosis. On multivariate analysis of posttransplant factors, high BMI (P < 0.001), serum triglycerides (P < 0.001), alcohol consumption (P = 0.005), and type 2 diabetes mellitus (P = 0.048) were associated with significant steatosis, whereas high creatinine (P = 0.02) appeared to protect against significant steatosis. Significant steatosis was not associated with a higher fibrosis stage (P = 0.62). Posttransplant steatosis affects 56.4% of LT recipients, and the prevalence increases with time after LT. Recipient factors and types of IS affect the risk for significant steatosis, which is not associated with a higher fibrosis stage or worse patient survival. Liver Transplantation 22 644-655 2016 AASLD. Topics: Adult; Alcohol Drinking; Alkaline Phosphatase; Biopsy; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Non-alcoholic Fatty Liver Disease; Prevalence; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Triglycerides | 2016 |